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MicroRNAs (miRNAs) have been implicated in B cell lineage commitment,
regulation of T cell differentiation, TCR signalling, regulation of IFN signalling,
and numerous other immunological processes. However, their function in auto-
immunity, and speciﬁcally in systemic lupus erythematosus (SLE), remains poorly
understood. B6.Sle123 is a spontaneous genetic mouse model of SLE character-
ized by autoantibody production, lymphosplenomegaly, and glomerulonephritis.
We identiﬁed several differentially regulated miRNAs in B and T lymphocytes of
B6.Sle123 mice. We found that miR-21 expression in lupus B and T cells is up-
regulated and that in vivo silencing of miR-21 using a tiny seed-targeting LNA
reversed splenomegaly, one of the cardinal manifestations of autoimmunity in
B6.Sle123 mice, and de-repressed PDCD4 expression in vivo and in vitro.I n
addition, treatment with anti-miR-21 altered CD4/CD8 T cell ratios and reduced
Fas receptor-expressing lymphocyte populations. Our study shows that tiny
LNAs can be used to efﬁciently antagonize endogenous miRNAs in peripheral
lymphocytesinvivoandinprimarylymphocytesculturedexvivoandcanalterthe
course of a spontaneous genetic disease in mice.
INTRODUCTION
Systemic lupus erythematosus (SLE, lupus) is an autoimmune
disease in which a combination of genetic predisposition and
possible environmental inﬂuences triggers an exaggerated
immune reaction against self-antigens and loss of immune
tolerance. Antibody production by B cells and aberrant
antibody-independent B and T cell functions have placed B
and T cells at the centre of development of new therapeutic
strategies for treatment of SLE [reviewed in (Crispin et al, 2010;
Sanz & Lee, 2010)]. The tri-congenic B6.Sle1.Sle2.Sle3
(B6.Sle123) mouse model bears three lupus susceptibility loci
from the NZM2410 lupus-prone strain, backcrossed onto a
C57BL/6 (B6) background (Morel et al, 2000). B6.Sle123 mice
spontaneously develop an autoimmune syndrome that strongly
resembles human lupus, characterized by autoantibodies
against H2A/H2B/DNA nucleosomes, splenomegaly, lympha-
denopathy, and immune complex-mediated glomerulonephri-
tis. Anti-histone autoantibodies are detected early in the life of
B6.Sle123 mice; however, splenomegaly and kidney disease are
not typically present until the age of 4–6 months (Morel et al,
2000). As in human SLE, autoimmune manifestations in
B6.Sle123 mice are associated with lymphocyte signalling
defects [reviewed in (La Cava, 2009; Liu & Mohan, 2009)]
and perturbation of cell proliferation and apoptosis (Mohan
et al, 1997; Mohan et al, 1999).
MicroRNAs (miRNAs) are  22nt non-coding RNAs that
regulate gene expression post-transcriptionally by mediating
translational repression or promoting degradation of their target
mRNAs (Filipowicz et al, 2008; Nelson et al, 2003). Animal
miRNAs have emerged as key players in diverse immunological
processes, such as B cell lineage commitment, regulation of T
cell differentiation, T cell receptor (TCR) signalling and
regulation of interferon (IFN) signalling (Lu & Liston, 2009;
Tang etal, 2009). However, their function in autoimmunity, and
speciﬁcally in SLE, remains poorly understood. Induction of
lymphoproliferative syndromes in mice by failed interaction of
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of the miR-17-92 cluster (Xiao et al, 2008) highlights an
important role for miRNAs in autoimmunity. Furthermore,
aberrant miRNA expression in lymphocytes and peripheral
blood mononuclear cells (PBMCs) from patients with SLE (Dai
et al, 2007; Te et al, 2010) and miRNA regulation of signalling
pathways involved in the induction or maintenance of lupus
(Divekar et al, 2011; Tang et al, 2009; Zhao et al, 2011) add
another layer of complexity to the molecular pathways that are
disordered in lupus.
In this study, we identiﬁed miRNAs differentially regulated in
peripheral lymphocytes in the mouse lupus model B6.Sle123.
We identiﬁed miR-21 as a constitutively overexpressed miRNA
in mouse SLE lymphocytes and showed that in vivo silencing of
miR-21 reversed cardinal manifestations of autoimmunity,
de-repressed PDCD4 expression and altered lymphocyte
populations in B6.Sle123 mice.
RESULTS AND DISCUSSION
Differential miRNA expression in B6.Sle123 peripheral
lymphocytes
We investigated whether miRNAs implicated in hematopoiesis
(Xiao et al, 2007), in activation of innate immune responses
(Taganov et al, 2006), and in apoptosis or cell proliferation (He
et al, 2007; Rokhlin et al, 2008; Yamakuchi & Lowenstein, 2009)
are differentially regulated in SLE and whether these miRNAs
play a role in SLE pathogenesis or course of the disease. To this
end, we isolated total RNA from ﬂuorescence-activated cell
sorting (FACS)-sorted splenic B and T lymphocytes from
individual B6.Sle123 mice and compared their miRNA expres-
sion proﬁles to those of control age-matched B6 mice.
Quantitative real-time polymerase chain reaction (qRT-PCR)
analysis showed that expression of several miRNAs is
differentially regulated in B6.Sle123 splenic B cells, naı ¨ve
(CD44
LO CD62L
HI) and memory (CD44
HI CD62L
LO) T cells
(Table 1), particularly from older mice (12 months of age),
which typically have advanced splenomegaly and kidney
disease (Fairhurst et al, 2008; Morel et al, 2000). For up-
regulated miRNAs, expression differences ranged from 1.8- to
13-fold. Speciﬁcally, in B6.Sle123 splenic B cells, miRs-21 and
222 were constitutively up-regulated relative to wild-type
controls and their expression increased with disease severity.
miR-181a was down-regulated in young and also in old mice
with severe disease. Expression of microRNAs miR-34a, 146a,
221, 223, 142-5p and miR-155 was up-regulated inold B6.Sle123
mice with severe disease (p<0.05, Table 1A). In naı ¨ve T cells,
miR-21wasalsoconstitutivelyup-regulatedrelativetowild-type
controls and its expression increased with disease severity.
miRs-221 and 155 were down-regulated in young B6.Sle123
micebutup-regulatedinmicewithseveredisease.Expressionof
miR-34a, 146a and 223 increased signiﬁcantly relative to wild-
type controls in mice with severe disease, while expression of
miR-222, 150 and 181a decreased (p<0.05, Table 1B). In
memory T cells, miR-21 and miR-146a were up-regulated
relative to wild-type controls in young and older mice. miR-221
expression increased in mice with severe disease. miR-155 was
down-regulated in young and old mice while miRs-34a, 221 and
223 were up-regulated and miR-181a was down-regulated in
older mice with severe disease (p<0.05, Table 1C). In
summary, interestingly, miR-21 expression was up-regulated
in lupus B cells as well as innaı ¨veand memory T cells compared
toB6controls,regardlessoftheageofmice(Table1andFig1A).
In contrast, miR-181a and miR-150 expression was down-
regulated in most lymphocyte subsets examined in lupus mice
compared to B6 controls (Table 1A–C).
The Sle2 locus in B6.Sle123 mice confers expansion of the
peritoneal and splenic B1-a B cell compartment (Mohan et al,
1997), even though the B2 subset remains the most abundant.
To evaluate the relative contribution of each cell subset to
individual miRNA abundance in the total pool of splenic CD19
þ
B cells from older SLE mice, we quantiﬁed the expression of
miR-21, miR-146a and miR-155 in B1-a and B2 subsets. We
detected the same trend for miR-21 and miR-146a expression in
both lupus B cell subgroups whereas miR-155 was up-regulated
only in B2 cells (Table 2). When lupus T cell subsets were
examined in older mice, a 10- and 24-fold up-regulation of miR-
21 was detected in CD4
þ and CD8
þ T cells, respectively, as well
as a signiﬁcant up-regulation of miR-146a and miR-155
compared to controls (Table 2).
Transcriptional activation of miR-21 in B6.Sle123
We found miR-21 expression to be consistently up-regulated in
all SLE cell subsets that we investigated. Notably, the fold
change of miR-21 expression in B6.Sle123 B lymphocytes,
compared to that from age- and gender-matched B6 mice,
positively correlated with the age of mice and thus with severity
of their disease (Fig 1A–C). To further dissect the role of miR-21
in mouse SLE, we asked whether transcription of miR-21 gene is
activated in lupus by comparing the expression of pri-miR-21 in
CD19
þ B cells isolated from 9 months old B6.Sle123 and age/
gender-matched B6. qRT-PCRanalysis revealedup-regulation of
pri-miR-21 transcript in B cells from lupus mice compared to
controls (Fig 1D). This indicates that, at least in part, miR-21 up-
regulation in B6.Sle123 B lymphocytes results from transcrip-
tional activation of miR-21 gene.
In vivo inhibition of miR-21 de-represses PDCD4 expression
in B6.Sle123 T cells
Since miR-21 has been shown to regulate apoptosis and cell
proliferation pathways (Chan et al, 2005; Cheng et al, 2005; Lu
et al, 2008; Sayed et al, 2010; Yang et al, 2004) and was
overexpressed in all subsets of lupus lymphocytes, we decided
to test whether in vivo inhibition of miR-21 in B6.Sle123 mice
could affect thecourse of theirdisease.The use ofLNA-modiﬁed
anti-miR oligonucleotides for miRNA silencing in vivo has been
previously demonstrated in rodents and non-human primates
(Elmen et al, 2008; Worm et al, 2009). Furthermore, recent
studies have described an approach that enables efﬁcient
antagonism of miR-21 function in vivo using a short LNA-
modiﬁedseed-targeting anti-miR-21oligonucleotide (Obadetal,
2011; Patrick et al, 2010). Thus, we designed a short-term
in vivo study in which three B6.Sle123 mice were injected
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miR-21 compound on three consecutive days and sacriﬁced
within 24h after the last dose. In control experiments, three age-
and gender-matched B6.Sle123 mice were treated with a LNA
scramble compound. Interestingly, our short-term study
showed that silencing of miR-21 in vivo results in approximately
20% de-repression of PDCD4 in naı ¨ve CD4
þ T cells from anti-
miR-21 treated mice, as compared to the PDCD4 expression in
naı ¨ve CD4
þ T cells from mice treated with control compound
(Fig 2B). PDCD4 is an inhibitor of translation initiation
(Zakowicz et al, 2005) and a tumour suppressor (Cmarik et
al, 1999; Jansen et al, 2005). Expression of PDCD4 is post-
transcriptionally regulated by miR-21 (Asangani et al, 2008;
Frankel et al, 2008). The function of PDCD4 in lymphocytes is
not yet understood but it is likely involved in cell proliferation
and/or apoptosis (Lankat-Buttgereit & Goke, 2009).
In vitro inhibition of miR-21 de-represses PDCD4 expression
in B6.Sle123 CD4
R T cells
We studied the expression of miR-21 and PDCD4 in primary
CD4
þTcellspuriﬁedfrom3monthsoldB6.Sle123micecultured
in presence of seed targeting LNA antimiR-21 or controls.
Primary CD4
þ T cells were puriﬁed and then mixed with culture
media containing LNA anti-miR-21, control compound or no
LNA. Cells were subsequently plated and harvested either
immediately (time 0) or at the indicated time points (Fig 2D).
Interestingly, miR-21 inhibition was observed at time 0,
indicating efﬁcient uptake of LNA compounds in the time
required to mix, plate and harvest the cells. This unassisted
uptake of LNA anti-miR-21 by primary CD4
þ T cells cultured
ex vivo resulted in a functional inhibition of miR-21 as shown by
de-repression of PDCD4 (Fig 2C and D). As expected, although
efﬁcient LNA uptake by the primaryT cells occurs within a short
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Table 1. miRNA expression in B6.Sle123 B and T lymphocytes
miRNA 2 mo. (mild disease) 6 mo. (moderate disease) 12 mo. (severe disease)
RQ
1 SEM p-value RQ
1 SEM p-value RQ
1 SEM p-value
A. Differential miRNA expression in B6.Sle123 splenic B Cells
miR-21 1.7 0.15 0.001 2.2 0.42 0.036 5.8 0.64 0.016
miR-34a 0.9 0.38 0.670 1.2 1.33 0.821 13.2 0.65 0.000
miR-146a 1.0 0.51 0.996 0.6 0.25 0.044 5.3 0.75 0.032
miR-221 1.2 0.29 0.504 1.2 0.28 0.398 13.3 1.05 0.023
miR-222 1.4 0.22 0.040 2.1 0.26 0.015 5.8 0.96 0.037
miR-223 0.9 0.53 0.720 2.3 1.61 0.507 11.4 0.68 0.006
miR-142-5p 1.1 0.21 0.374 0.4 0.34 0.017 2.7 0.45 0.032
miR-155 1.3 0.12 0.026 1.2 0.39 0.504 2.8 0.53 0.050
miR-150 0.7 0.45 0.314 0.5 0.27 0.098 0.5 0.18 0.006
miR-181a 0.5 0.20 0.007 0.3 0.78 0.069 0.4 0.36 0.020
B. Differential miRNA expression in B6.Sle123 splenic naı ¨ve T cells
miR-21 2.5 0.37 0.012 3.6 1.00 0.110 3.0 0.58 0.032
miR-34a 1.5 0.91 0.528 4.2 1.05 0.094 6.2 0.50 0.006
miR-146a 1.0 1.20 0.955 4.9 1.56 0.216 4.1 0.31 0.002
miR-221 0.3 0.47 0.013 2.3 1.40 0.433 4.0 0.39 0.002
miR-222 0.6 0.49 0.187 1.2 0.50 0.672 0.5 0.20 0.006
miR-223 1.2 0.55 0.697 4.6 0.58 0.019 11.1 0.23 0.000
miR-142-5p 1.0 0.33 0.906 1.3 0.56 0.550 2.6 0.46 0.027
miR-155 0.5 0.12 0.000 2.1 1.40 0.475 2.1 0.17 0.000
miR-150 1.0 0.84 0.943 0.7 0.69 0.553 0.6 0.22 0.008
miR-181a 1.4 0.77 0.562 1.0 0.97 0.980 0.2 0.66 0.015
C. Differential miRNA expression in B6.Sle123 splenic memory T cells
miR-21 2.3 0.26 0.00371 2.3 0.32 0.00935 2.9 0.31 0.00734
miR-34a 1.2 0.46 0.61619 2.8 0.98 0.17000 6.1 1.0 0.03999
miR-146a 2.0 0.27 0.00815 1.9 0.23 0.00692 1.8 0.31 0.03301
miR-221 0.9 0.29 0.78955 2.2 0.33 0.02462 3.5 0.59 0.01522
miR-222 3.0 0.66 0.04896 2.5 0.39 0.02568 4.7 0.91 0.03822
miR-223 1.1 0.44 0.80584 1.7 0.14 0.00425 5.3 0.89 0.02602
miR-142-5p 1.2 0.22 0.35640 1.3 0.39 0.38912 0.9 0.52 0.72454
miR-155 0.1 0.86 0.02879 1.3 0.30 0.91145 0.1 0.31 0.00023
miR-150 1.3 0.36 0.34351 1.1 0.50 0.80519 1.0 0.68 0.92495
miR-181a 0.8 0.33 0.49138 0.9 0.98 0.93433 0.2 0.79 0.01509
A. CD19
þ splenic B cells from individual B6.Sle123 and age- and gender-matched B6 mice at 2, 6 and 12 months of age were FACS puriﬁed. Twenty nanograms
total B cell RNA were reverse-transcribed with TaqMan miRNA-speciﬁc reverse-transcription primers followed by quantiﬁcation using Taqman miRNA-speciﬁc
qRT-PCR assays. B6.Sle123 miRNA RQ values represent the average of triplicate measurements from at least three independent experiments in individual
B6.Sle123 mice relativeto the expression of the same miRNA in individual B6 B cells. Prior to obtaining RQ values, the Ctvalues for each miRNA in each sample,
were normalized against sno429 expression (DCt). The mean B6.Sle123 miRNA RQ was calculated by evaluating 2 DDCt where DDCt¼DCt Sle123 ave DCt B6 ave.
B. As in A except total splenic CD44
Low CD62L
High naı ¨ve T cells were FACS puriﬁed from individual mice.
C. As in A except total splenic CD44
High CD62L
Low memory T cells were FACS puriﬁed from individual mice.
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Figure 1. miR-21 expression in B6.Sle123 is regulated transcriptionally and correlates with age and disease severity.
A. pre-miR-21 and mature miR-21 expression in B6.Sle123 splenic B cells. Twenty micrograms of total splenic B cell RNA from individual age-matched 2, 6
and 12 months old B6.Sle123 and B6 mice were analysed under denaturing conditions, transferred and hybridized with LNA probe complementary
to miR-21. For mass-normalization, the same membrane was stripped and re-probed with mouse snoRNA-429 radiolabelled DNA probe. The data were
normalized to snoRNA-429 expression and relative fold-expression values calculated by taking the B6.Sle123/B6 ratio. A shorter exposure of the same
membrane was used for the detection of the miR-21.
B. B6.Sle123 disease severity correlates with age: BUN of 2, 6 and 12 months old female B6 and B6.Sle123 mice used as a measure of disease
severity.
C. Comparison of spleens extracted from 6 months old B6 and B6.Sle123 mice showing correlation of BUN and splenomegaly.
D. qRT-PCR amplification of primary miR-21 (pri-miR-21) using splenic B cell RNA from individual, age-matched 9 months old B6.Sle123 and B6 mice. The
average of three individual experiments is shown. Error bars represent SEM.
Table 2. miRNA expression in B6.Sle123 lymphocyte subsets
miRNA RQ1 SEM (p-value)
CD5
  B2 B cells CD5
þ B1a B cells CD4
þ T cells CD8
þ T cells
miR-21 5.2 0.85 (0.048) 2.7 1.30 (0.329) 10.2 0.76 (0.011) 24.4 0.97 (0.009) (0.0090)
miR-146a 1.9 1.09 (0.456) 1.9 0.83 (0.319) 5.4 0.48 (0.007) 19.4 0.93 (0.010)
miR-155 2.1 0.35 (0.038) 0.94 1.6 (0.954) 2.9 0.03 (0.0001) 7.5 0.69 (0.014)
As in Table 1A expect CD5
  B2 and CD5
þ B1a B cells and CD4
þ and CD8
þ T cells were FACS puriﬁed from individual  12 months old B6.Sle123 and
age- and gender matched B6 mice. Standard error and p-values were calculated using an un-paired, two-tailed Student’s t-test.
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subsequent time points (48 and 72h). Our results indicate that
seed-targeting LNA anti-miR-21 can silence endogenous miR-21
efﬁciently and in a very short period of time in primary
B6.Sle123 T lymphocytes cultured ex vivo.
In vivo inhibition of miR-21 ameliorates splenomegaly
in B6.Sle123 mice
To study the effect of in vivo miR-21 silencing in lupus, we
treated 9-week-old female SLE mice by injecting them with anti-
miR-21. Control mice were injected with LNA scramble or
saline. Twelve 9-weeks-old female B6.Sle123 mice were
randomly assigned to four groups. Mice in each group received
injections of either LNA anti-miR-21 at a dose of 25mg/kg, LNA
scramble control compound at the same dose, or saline vehicle.
All mice received intraperitoneal (IP) injections on three
consecutive days and subsequent maintenance IP injections
of 25mg/kg every 3 weeks over a period of 3 months. The last
injection was given intravenously. All mice were sacriﬁced
within 24h after the last dose. Spleens were extracted, weighed
and subsequently, splenic lymphocytes were sorted. Northern
blot analysis of total RNA isolated from liver or splenic B cells
indicated that miR-21 was sequestered in a slower-migrating
heteroduplex with the anti-miR-21 in the liver and in B cells
(Fig 3A). Notably, silencing of miR-21 in vivo resulted in a
signiﬁcant reduction of splenomegaly in the SLE mice treated
with anti-miR-21 compared to the LNA scramble- and
vehicle control-treated mice in all four groups (Fig 3B and C).
All mice survived the treatment with no observable change in
the behaviour to suggest toxicity or intolerance to the treatment.
Furthermore, no gross pathologic abnormalities were observed
in the spleens (Fig 3B), livers, kidneys or other organs examined
macroscopically during the necropsy at the completion of
the study.
Inadditiontotheobservedreduction insplenomegaly,in vivo
miR-21 silencing resulted in a signiﬁcant decrease in the splenic
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Figure 2. Silencing of miR-21 by tiny LNA-anti-miR in vivo and in vitro derepresses PDCD4 in B6.Sle123 T cells.
A. Three groups of two B6.Sle123 mice were treated in vivo with seed-targeting LNA antimiR-21 or LNA scramble control compound daily for 3 days.
miR-21 qRT-PCR quantification using total RNA from CD4
þ T cells FACS purified from LNA antimiR-21- and LNA scramble compound-treated mice. Mean RQs
of three independent experiments.
 p¼8.1 10
 6.
B. Western blot analysis of PDCD4 expression in CD4
þ T cells derived from in vivo LNA antimiR-21 treated mice and controls. Results are representative of three
independent experiments.
C. Unassisted uptake of LNA antimiR-21 by primary B6.Sle123 CD4
þ T cells maintained in culture. Cells were purified, cultured in the presence of tiny seed-
targeting LNA antimiR-21 or control compound as described in Materials and Methods section. At selected time points, cells were harvested and miR-21
expression was assessed by real-time PCR.
D. PDCD4 expression in CD4
þ T cells treated in vitro with seed-targeting LNA antimiR-21 or control compound.
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Figure 3. Silencing of miR-21 in vivo by tiny LNA-anti-miR ameliorates splenomegaly in B6.Sle123.
A. In vivo sequestration of miR-21 by seed-targeting LNA antimiR-21 in a slower migrating heteroduplex. Four groups of mice were treated with either saline
(n¼4), or LNA-scramble control compound (n¼4) or tiny LNA antimiR-21 (n¼4) over a period of 12 weeks. Native Northern blot analysis of total RNA
extractedfrom livertissue(top panels) or from purified splenic B220
þ B cells (lower panels) was performed using a radiolabelled DNA probe complementary to
miR-21. The first and second sample in each panel corresponds to in vitro annealed miR-21/LNA anti-miR-21 duplex and synthetic miR-21, respectively, used
as controls.
B. Effect of in vivo miR-21 silencing in autoimmune splenomegaly. Individual spleens harvested from the four groups of mice treated in the study are shown.
(i, ii, iii indicate treatment with saline, LNA scramble and LNA antimiR-21, respectively).
C. Meanspleenmassesplottedasspleen-mass(mg)/mousebodymass(g)ratios.ErrorbarsrepresenttheSEMofthefourindependentexperiments.p-valueswere
calculated using an un-paired, two-tailed t-test.
 p¼0.0149,
  p¼0.000127.
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þ to CD8
þ T cell ratio and a reduction in the number of Fas
receptor-expressing splenic B cells (Fig 4 and Table 3).
Interestingly, elevated CD4
þ to CD8
þ ratios are a characteristic
phenotypic alteration in Sle3-bearing T lymphocytes (Mohan
et al, 1999). Thus, our results suggest that miR-21 inhibition
skews the CD4
þ to CD8
þ ratio towards that of the background
non-autoimmune strain (Mohan et al, 1999). In the LNA
scramble-treated group, we observed increased CD4
þ to CD8
þ
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Figure 4. Silencing of miR-21 in vivo results in altered CD4/CD8 T cell ratios and reduced populations of Fas receptor-expressing B cells. Four groups
of B6.Sle123 mice were treated in vivo with LNA antimiR-21 or controls for 12 weeks, as described in the text. Splenocytes from B6.Sle123 mice injected with
saline (left panels), LNA scramble control (middle panels) or LNA antimiR-21 (right panels) were stained with appropriate fluorophore-conjugated antibodies and
subjected to flow cytometry.
A. Top panels: CD4
þ and CD8
þ populations from the four treatment groups plotted as the percentage of viable lymphocytes. Horizontal bar indicates the mean
value.TopRight:ChartofthemeanCD4/CD8ratiosinthefourtreatmentgroups.
 p¼0.0135,
  p¼0.0025.Bottompanels:representativeflowcytometryplots
from one treatment group.
B. Toppanels:FasR
þIgD
 populationsfromthefourtreatmentgroupsplottedasthepercentageofCD19
þB220
þlymphocytes.Horizontalbarindicatesthemean
value. Bottom panels: representative flow cytometry plots from one treatment group.
www.embomolmed.org EMBO Mol Med 3, 605–615  2011 EMBO Molecular Medicine 611ratios due to an expansion of the CD4
þ cells. Anti-chromatin
antibody titers and blood urea nitrogen (BUN) levels were not
affected by miR-21 silencing in this study (data not shown).
Our work demonstrates aberrant miRNA expression in
B6.Sle123 lymphocytes at different stages of mouse SLE.
Although we focused only on a small set of miRNAs, it is
likely that other miRNAs not tested in this study are also
differentially regulated. The up-regulation of miR-21 was of
particular interest since it is detected in old and young mice and
thus precedes severe SLE manifestations. Importantly, up-
regulation of miR-21 in B and T lymphocytes preceding SLE
manifestations was reported recently in the MRL/lpr, another
genetic mouse model of lupus. Furthermore, miR-21 is also
upregulated in human lupus CD4
þ T and B cells and PBMCs
(Pan et al, 2010; Te et al, 2010). Combined with our studies, this
recent evidence implies an important role for miR-21 in the
disordered immunoregulation in SLE.
Our study shows that seed-targeting tiny LNAs can be used
for in vivo inhibition of miR-21 in rapidly proliferating cells,
such as splenic lymphocytes. Efﬁcient, unassisted uptake of tiny
LNAs in cultured cell lines has been recently reported (Obad
et al, 2011); our study is the ﬁrst to show unassisted uptake of
tiny seed-targeting LNAs by primary T lymphocytes.
Furthermore, our in vivo and in vitro studies showed that
miR-21 regulates PDCD4 in SLE T lymphocytes. PDCD4 is
directly targeted by miR-21 (Asangani et al, 2008; Frankel et al,
2008; Reis et al, 2010) and regulates pathways involved in
apoptosis, cell cycle and differentiation [reviewed in (Lankat-
Buttgereit & Goke, 2009)]. In pancreatic adenoma, miR-21
silencing induces PDCD4, promotes cell proliferation, and
inhibits apoptotic cell death (Bhatti et al, 2011). PDCD4
promotes activation of the transcription factor NF-kB, sup-
presses IL10 and regulates TLR4 signalling (Sheedy et al, 2010).
PDCD4-deﬁcient mice develop B cell lineage lymphomas and
their lymphocytes produce increased IL-10, IL-4 and IFN
gamma, cytokines with important functions in T cell differ-
entiation (Hilliard et al, 2006). The function of PDCD4 in SLE is
not yet understood, however, it is likely that PDCD4 controls
apoptotic or cell proliferation pathways contributing to the
immunologic phenotype of B6.Sle123. It is also likely that
PDCD4, via miR-21, regulates cell-signalling pathways partici-
pating in the orchestration of the cross talk between hyperactive
B and T cells in lupus.
To investigate the function of miR-21 in mouse SLE, we
designed a long term in vivo miR-21 knockdown study and
demonstrated signiﬁcant amelioration in splenomegaly,
induced speciﬁcally by treatment with the anti-miR-21 but
not the LNA control compound.
Mice treated in our study were young and miR-21 inhibition
likely interfered with mechanisms inducing splenomegaly in
lupus mice, altering the natural course of the disease. The
severity of kidney disease by the age of 5 months varies in
B6.Sle123. This could be the reason that in this model, miR-21
inhibition did not result in statistically signiﬁcant BUN change
between LNA antimiR-21-treated mice and controls. Inhibition
of splenomegaly suggests that miR-21 controls cellular path-
ways important for cardinal disease manifestations in B6.Sle123
and is consistent with recent reports showing that miR-21
silencing reverses lymphosplenomegaly in mice with pro-B cell
lymphoma (Medina et al, 2010). Two studies published while
our manuscript was under review have shed further light
on the role of miR-21/PDCD4 in immune activation and
tolerance (Iliopoulos et al, 2011) and demonstrated correlation
of miR-21/PDCD4 expression with human SLE disease activity/
remission (Stagakis et al, 2011). Furthermore, aberrant T cell
responses in active SLE and T cell-driven B cell functions in
human lupus were connected to the function of miR-21
(Stagakis et al, 2011). Together with our functional results,
this new evidence supports a central role for miR-21/PDCD4-
controlled pathways in mouse and human lupus. Further
elucidation of these pathways with studies inmouse models and
human cells will shed light on the molecular complexity of this
prototype autoimmune disease.
In summary, our study shows that tiny seed-targeting LNAs
can be used to efﬁciently antagonize endogenous miRNAs in
peripheral lymphocytes in vivo and in vitro and that pharma-
cological inhibition of a miRNA using such compounds can alter
the course of a spontaneous genetic disease in mice. Our work,
together with a recent study showing efﬁcient silencing of
miRNA families by seed-targeting LNAs (Obad et al, 2011),
opens new directions for investigations of tiny LNAs as
novel therapeutic tools. In addition, our results in a mouse
model of lupus corroborated by recent studies in human SLE,
indicate that miR-21 plays a central role in regulating
autoimmune responses in lupus and that miR-21 inhibition
can favourably alter the course of a systemic autoimmune
process, opening new directions for explorations of miRNA
therapeutics in SLE.
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Table 3. In vivo miR-21 silencing skews T and B lymphocyte subsets in
B6.Sle123
a
Treatment group
Saline LNA
scramble
LNA
antimiR-21
Total splenocytes ( 10
6)
b 392 74.5 335 82.2 373 106.5
T cells
Events 250 10
3 250 10
3 250 10
3
Viable ( 10
3)
c 199.3 15.1 201.6 9.5 207.8 3.9
CD4
þ ( 10
3)
d 36.2 7.5 35.6 4.4 39.8 2.5
CD8
þ ( 10
3)
d 7.8 2.1 5.2 0.4 17.0 5.9
 
y
CD4
þ/CD8
þ ratio 4.7 0.6 6.9 1.3 2.6 1.1
B cells
Events 1 10
6 1 10
6 1 10
6
Viable ( 10
3)
c 617.9 77.5 565.2 56.1 607.6 93.0
CD19
þ B220
þ ( 10
3)
c 265.0 88.2 127.3 88.8 268.8 50.6
FasR
þ IgD
  ( 10
3)
e 38.8 19.4 25.4 14.7 20.9 7.1
aValues represent the mean SD (n¼4 mice in each treatment group).
bSpleens were harvested and single-cell suspensions prepared as described in
Materials and Methods section. Viable cells were identiﬁed on the basis of
trypan blue staining.
cViable lymphocyte populations were identiﬁed post-collection.
dGated on the viable lymphocyte population.
eGated on the CD19
þ B220
þ population.
 p¼<0.01 compared to LNA
scramble.
yp¼0.01 compared to Saline.
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Mice
Breeder pairs of B6.Sle1Sle2Sle3 (B6.Sle123) (Morel et al, 2000) mice
were a kind gift from Dr. Laurence Morel (University of Florida,
Gainesville). B6.Sle123 or C57BL/6 (B6) (Jackson Laboratory, Bar Harbor,
ME, USA) mice were bred and maintained in pathogen-free, Institutional
Animal Care and Use Committee (IAUCAC)-approved animal facility at
the University of Pennsylvania. Care and experimental procedures were
approved by the IACUC at the University of Pennsylvania. BUN was
measured in freshly drawn cardiac blood (Azostix reagent strips,
Siemens Healthcare Diagnostics Inc.). BUN of 5–15mg/dL was
considered consistent with no detectable renal disease, 15–26mg/dL
consistent with mild disease, 30–40mg/dL consistent with moderate
disease and 50–80mg/dL consistent with severe disease.
Antibodies
Rat anti-mouse CD19 (1D3), CD44 (IM7), CD44 (30-F11), CD62L
(MEL-14), CD19 (1D3) and hamster anti-mouse CD3e (145-2C11),
CD69 (H1.2F3), CD11c (HL3), were purchased from BD Pharmingen.
Rat anti-mouse CD45R (B220; RA3-6B2), CD5 (53-7.3), CD4 (L3T4),
CD4 (GK1.5), CD4 (GK1.5), CD8 (53-6.7), IgD (11-26c), hamster anti-
mouse CD3e (145-2C11), and mouse anti-mouse CD95 (APO-1/FasR;
15A7) were from eBioscience.
Splenocyte preparation and lymphocyte purification
All procedures were performed on ice in FACS buffer (1X DPBS (Ca
2þ/
Mg
2þ free); 0.5% BSA; 2mM EDTA). Single-cell suspensions were
prepared by crushing spleens between frosted glass slides. Cells were
blocked with rat anti-mouse CD16/32 (2.4G2) monoclonal antibody
(mAb) for 15min at room temperature (RT) and stained for 30min on
ice with appropriate fluorophor-conjugated antibodies. Dead cells
were excluded from FACS by staining with DAPI. FACS sorting was
performed at 48C on a FACSAria cytometre (BD Biosciences) to a purity
>95%. Alternatively, B cells were purified using autoMACS magnetic
cell separation columns. Following purification, cells were either
pelleted and snap-frozen or processed immediately.
Flow cytometry
All flow cytometry experiments were performed on a Becton
Dickinson FACSCalibur at the University of Pennsylvania and the
acquired data analysed with the FloJo software package (Tree
Star Inc.).
RNA purification and quantitative real-time PCR
Total RNA was extracted using either Trizol reagent (Invitrogen) or the
mirVana miRNA Isolation Kit (Ambion). For miRNA-specific reverse
transcription (RT), 20ng purified total RNA was reverse-transcribed
(TaqMan miRNA-specific RT PCR primers, Applied Biosystems). qRT-
PCR was performed in triplicates using 1:10 dilution of the RTproduct
(Applied Biosystems 7500 real-time PCR system, according to the
manufacturer’s instructions). snoRNA-429 expression was used as
control. Relative quantification (RQ) of B6.Sle123 miRNA expression
was assessed by calculating the 2 DDCt where DDCt ¼ DCtSle123 
DCtwild-type and DCt ¼ CtmiRNA CtsnoRNA.
For qRT-PCR amplification of the primary miR-21 (pri-miR-21),
primers (F: 50-TGA CAT CGC ATG GCT GTA-30 and R: 50-GAT GCT GGG
TAA TGT TTG AAT G-30) spanning a 209nt sequence containing the
mouse pre-miR-21, were designed by identifying a mouse genomic
sequence, with 91% similarity to the human primary miR-21.
Splenic B cells (CD19
þ) were isolated from 3 nine months old
B6.Sle123 and three age- and gender-matched C57BL/6
and B6.Sle123 mice using anti-CD19 MACS microbeads (Miltenyi
Biotec, Germany). Total RNA was extracted with Trizol (Invitrogen)
and double treated with TURBO DNase (Ambion, Inc., Austin, Texas,
USA) to remove genomic DNA. Six hundred nanograms of total RNA
was reverse-transcribed (Random primers, Applied Biosystems and
Superscript III Reverse Transcriptase, Invitrogen). qRT-PCR was
performed in triplicates using ½ of the RT product for pri-miR-21
and ½ for b-actin amplification (b-actin primers from Applied
Biosystems Mm 00607939_S1). No-RT (-RT) RNA was used as
negative control to exclude amplification due to genomic DNA
contamination. RQ of B6.Sle123 pri-miR-21 expression was assessed
by calculating the 2 DDCt, where DDCt¼DCtB6.Sle123 DCtC57BL/6 and
DCt¼Ctpri-miR-21 Ctb-actin.
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The paper explained
PROBLEM:
Systemic lupus erythematosus (SLE) is a potentially fatal
systemic autoimmune disease. The pathogenesis of SLE is poorly
understood, however, aberrant functions of the immune system
place B and T lymphocytes at the centre of investigations for
novel therapeutic targets. miR-21 is implicated in cancer,
however, its function in autoimmunity and specifically in SLE is
poorly understood.
RESULTS:
This study identifies a set of miRNAs differentially expressed
in peripheral lymphocytes in a mouse model of SLE. miR-21 is
up-regulated in all lymphocyte subsets examined. In vivo and in
vitro silencing of miR-21 using small, seed targeting LNA
inhibitors de-represses PDCD4, a protein involved in cell
proliferation and apoptosis and ameliorates cardinal SLE
manifestations in mouse lupus.
IMPACT:
This work provides evidence for the involvement of miR-21 in SLE.
Furthermore, this study is the first to show that pharmacological
in vivo inhibition of miR-21 using seed-targeting LNAs can alter
the course of a spontaneous, genetic disease in mice. Our work
opens new directions for the use of small LNA inhibitors as
therapeutic tools in autoimmune diseases.
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Total RNA samples were resolved on 15% urea-polyacrylamide gels
(20% polyacrylamide for native Northern blots), transferred to
nitrocellulose membranes, hybridized with radiolabelled DNA or LNA
probes complementary to miR-21. snoRNA-429 expression was used
for normalization. Detection and analysis: Storm 860 (Molecular
Dynamics) and ImageQuant (GE).
Protein isolation and Western blot analysis
Purified cell populations were pelleted, washed with PBS then re-
suspended RIPA buffer (Pierce Biotechnology) supplemented with
protease and phosphatase inhibitors (Roche Diagnostics). Proteins
were resolved on NuPAGE 4-12% bis–tris polyacrylamide gels
(Invitrogen Corp., Carlsbad, CA) and transferred to nitrocellulose
membranes (Invitrogen). Primary antibodies: PDCD4 (Cell Signaling)
and b-actin (Sigma). Proteins were visualized using the ECL Western
Blotting Detection System (GE Healthcare). Protein bands were
quantified using the ImageQuant software.
In vivo experiments
The 8-mer seed-targeting antimiR-21 (50-GATAAGCT-30) and 8-mer
LNA scramble control (50-TCATACTA-30) oligonucleotides were synthe-
sized as unconjugated, fully LNA-substituted oligonucleotides with a
complete PS backbone as described (Patrick et al, 2010) and
formulated in physiological saline (0.9% NaCl). For short-term
experiments, six 8-weeks-old female B6.Sle123 mice were randomly
assigned to three groups. The mice in each group received three
intravenous (retro-orbital) injections of either LNA antimiR-21 or LNA
scramble compounds (25mg LNA/kg mouse body weight) on
consecutive days. The mice were sacrificed within 24h after the last
dose. For long-term experiments, twelve 9-weeks-old female
B6.Sle123 mice were randomly assigned to four groups and mice in
each group received IP injections of either LNA antimiR-21, LNA
scramble control compound, or saline. The mice were weighed
immediately prior to dosing and received a dose of 25mg LNA/kg
mouse body wt. All mice received three initial IP injections on
consecutive days and subsequent booster injections of 25mg/kg every
3 weeks over a period of 3 months. The last booster injection was via
intravenous delivery. All mice were sacrificed within 24h after the last
dose.
Statistical analysis
Reported B6.Sle123 mean miRNA expression differences represent
triplicate measurements from at least three independent experiments
in individual age- and gender-matched B6 and B6.Sle123 mice.
Standard errors and p-values were calculated with an un-paired, two-
tailed Student’s t-test.
Ex vivo T cell culture and miR-21 inhibition
Spleens from 3 months old B6.Sle123 mice were harvested and single-
cell suspensions prepared as described. Splenocytes were pooled and
CD4
þ T cells purified by incubation with anti-CD4 MACS microbeads
(L4T4) followed by separation on MACS LS columns (Miltenyi Biotec,
Auburn, CA) according to the Manufacturer’s instructions. The purity
was >90% CD4
þ, as determined by flow cytometry. Cells were
resuspended (10
6 cells/ml) in RPMI 1640 media (supplemented
with 10% FBS, 25mM HEPES, 100U/ml penicillin/streptomycin, 2mM
L-glutamine, 1% non-essential amino acids, 50mM 2-mercaptoetha-
nol and 100U/ml IL-2) containing either PBS, 50mM LNA scramble
oligonucleotide or 50mM LNA antimiR-21 and plated in 96-well
round-bottom plates (1 10
6 cells/well) and maintained at
378Cþ5% CO2. At selected time points, cells were harvested and
miR-21 expression was assessed by qRT-PCR.
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